In the future, anti-inflammatory cytokine kinetics pre- and post-pioglitazone treatment should be studied in monocytes of CGD subjects, which will make PPARγ agonist, specifically pioglitazone treatment therapy, more promising. This evidence concerns the gene PPARG and chronic granulomatous disease.